Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, John C Byrd, Richard R Furman, Peter Hillmen, Anders Osterborg, Constantine Tam, Stephan Stilgenbauer, William G Wierda, Nyla A Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D Chu, Danelle F James, Susan M O'Brien
British Journal of Haematology | WILEY | Published : 2018
We thank the patients who participated in these studies, their supporters, and the investigators and clinical research staff from the study centres. This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.